Chapman Steven Leonard sold $1.6M of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 3,801 shares of Natera, Inc. (NTRA) at an average of $411.80 ($387.90–$415.64, $1.57M total) across 3 trades on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Nov 5, 2026, 2:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosed sale may cause short‑term price softness but is unlikely to drive a sustained move.

02

Market read

A modest insider sell by the CEO provides a small, actionable data point for short‑term traders.

03

What to watch

The CEO still holds a sizable position, and the sale was pre‑arranged under a 10b5‑1 plan.

Relevance 5/10Novelty 4/10Timing: after market close on 2026-11-02

Background

Form 4 filings disclose insider transactions; investors watch CEO sales for potential signals.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

CEO Steven Leonard sold 3,801 shares for $1.56M via a 10b5‑1 plan, reducing his stake to 87,431 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $1.6M sale by the CEO is a material insider transaction, but the amount is modest relative to market cap, so impact is limited.

Market effects

Minimal; the sale does not affect the broader genetic testing sector.

None

Low

Counterpoint

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • Steven Leonard

    CEO and President of Natera, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.